The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
GW 3965 results in increased expression of ABCA1 mRNA GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]; NR1H3 mutant form inhibits the reaction [GW 3965 results in increased expression of ABCA1 mRNA] GW 3965 results in increased expression of ABCA1 mRNA; GW 3965 results in increased expression of ABCA1 protein NR1H2 protein affects the reaction [GW 3965 results in increased expression of ABCA1 mRNA]; NR1H3 protein affects the reaction [GW 3965 results in increased expression of ABCA1 mRNA] GW3965 increases degradation of cell surface resident ABCA1 protein in HepG2 cells
GW 3965 results in increased expression of ABCG1 mRNA GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]
GW 3965 results in increased expression of APOE mRNA NR1H2 protein affects the reaction [GW 3965 results in increased expression of APOE mRNA]; NR1H3 protein affects the reaction [GW 3965 results in increased expression of APOE mRNA] GW 3965 results in increased expression of and results in increased secretion of APOE protein GW 3965 promotes the reaction [Decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of APOE mRNA]]
GW 3965 inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]
GW 3965 results in increased expression of CYP3A4 mRNA [GW 3965 co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of FASN mRNA] [Bexarotene co-treated with GW 3965] results in increased expression of FASN mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of FASN mRNA GW 3965 results in increased expression of FASN mRNA
GW 3965 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA] GW 3965 results in increased expression of ICAM1 mRNA
GW 3965 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] GW 3965 inhibits the reaction [IL6 protein results in increased expression of SOCS3 protein]; GW 3965 inhibits the reaction [IL6 protein results in increased expression of STAT3 protein modified form]
GW 3965 results in increased expression of NR0B2 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of NR0B2 mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of NR0B2 mRNA
GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H2 mRNA]; GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H2 protein]; NR1H2 protein affects the reaction [GW 3965 results in increased expression of ABCA1 mRNA]; NR1H2 protein affects the reaction [GW 3965 results in increased expression of APOE mRNA] [GW 3965 co-treated with NR1H3 protein] results in decreased expression of NR1H2 mRNA; GW 3965 inhibits the reaction [NR1H2 protein results in increased expression of NR1H3 mRNA]; GW 3965 inhibits the reaction [NR1H2 protein results in increased expression of POU5F1 mRNA]
[Bexarotene co-treated with GW 3965] results in increased expression of NR1H3 mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of NR1H3 mRNA; [GW 3965 co-treated with NR1H3 protein] results in decreased expression of NR1H2 mRNA; [GW 3965 co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA; GW 3965 binds to and results in increased activity of NR1H3 protein; GW 3965 inhibits the reaction [NR1H2 protein results in increased expression of NR1H3 mRNA]; NR1H3 mutant form inhibits the reaction [GW 3965 results in increased expression of ABCA1 mRNA] GW 3965 results in increased expression of NR1H3 mRNA GW 3965 binds to and results in increased activity of NR1H3 protein; GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H3 mRNA]; GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H3 protein]; NR1H3 protein affects the reaction [GW 3965 results in increased expression of ABCA1 mRNA]; NR1H3 protein affects the reaction [GW 3965 results in increased expression of APOE mRNA] GW 3965 results in increased activity of NR1H3 protein GW 3965 promotes the reaction [decitabine inhibits the reaction [Cadmium results in decreased expression of NR1H3 mRNA]]
GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H4 mRNA]; GW 3965 inhibits the reaction [Palmitic Acid results in decreased expression of NR1H4 protein]
[Bexarotene co-treated with GW 3965] results in increased expression of NRIP1 mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of NRIP1 mRNA
GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]
GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of SCD1 mRNA] [Bexarotene co-treated with GW 3965] results in increased expression of SCD mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of SCD mRNA GW 3965 results in increased expression of SCD mRNA
GW 3965 results in increased expression of SREBF1 mRNA; GW 3965 results in increased expression of SREBF1 protein [Bexarotene co-treated with GW 3965] results in increased expression of SREBF1 mRNA; [CD 3254 co-treated with GW 3965] results in increased expression of SREBF1 mRNA; puag-haad inhibits the reaction [GW 3965 results in increased expression of SREBF1 protein]; Resveratrol inhibits the reaction [GW 3965 results in increased expression of SREBF1 protein] GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 mRNA]; GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
GW 3965 inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA] GW 3965 results in increased expression of VCAM1 mRNA